Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03750552 · ClinicalTrials.gov registry record · Phase 3
Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3 study of Symptomatic Neurogenic Orthostatic Hypotension, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 195
- Enrollment target
- 20
- Study locations
NCT03750552 is a Phase 3 study of Symptomatic Neurogenic Orthostatic Hypotension that has completed, run by Theravance Biopharma. The registered enrollment target is 195 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT03750552, a Phase 3 study of Symptomatic Neurogenic Orthostatic Hypotension, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 195 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH with up to 4 weeks of treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ampreloxetine
Study Locations (20)
Florida
- Parkinson's Disease and Movement Disorders Center - Boca Raton
- SFM Clinical Research - Boca Raton
- Fixel Institute for Neurological Diseases - Gainesville
- Neurostudies, Inc - Port Charlotte
California
- Collaborative Neuroscience Network, LLC - Long Beach
- Stanford Neuroscience Health Center - Palo Alto
Colorado
- Colorado Springs Neurological Associates, PC - Colorado Springs
- University of Colorado Health - Loveland
Illinois
- Rush University Medical Center - Chicago
- NorthShore University Health System - Glenview
Ohio
- University of Cincinnati Medical Center - Cincinnati
- The Ohio State University Wexner Medical Center - Columbus
Arizona
- Banner Sun Health Research Institute - Sun City
District of Columbia
- Georgetown University Hospital, Dept. of Neurology - Washington D.C.
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2019-01-24 |
| Est. Completion | 2021-07-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03750552
The ClinicalTrials.gov registry entry for NCT03750552 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Symptomatic Neurogenic Orthostatic Hypotension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03750552 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03750552 about?
NCT03750552 is a clinical study titled "Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure". A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH with up to 4 weeks of treatment.
What is the current status of trial NCT03750552?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 195 participants. The study started on 2019-01-24. Estimated completion is 2021-07-21.
What conditions does trial NCT03750552 study?
This clinical trial studies the following conditions: Symptomatic Neurogenic Orthostatic Hypotension.
What interventions are being tested in trial NCT03750552?
The interventions under investigation include: Placebo (DRUG), ampreloxetine (DRUG).
Who is sponsoring clinical trial NCT03750552?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03750552 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Symptomatic Neurogenic Orthostatic Hypotension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.